Lifecore Biomedical, Inc. De (LFCR) Asset Writedowns and Impairment (2015 - 2023)

Lifecore Biomedical's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $1.0 million for Q2 2023.

• In Q2 2023, Asset Writedowns and Impairment fell 97.83% year-over-year to $1.0 million; the TTM figure through Feb 2024 stood at $1.0 million (down 97.83% YoY), while the FY2023 annual figure was $1.3 million, down 98.34% from the prior year.
• Asset Writedowns and Impairment was $1.0 million for Q2 2023 at Lifecore Biomedical, up from -$1.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $46.1 million in Q2 2022 to a low of -$1.0 million in Q1 2023.
• Historically, Asset Writedowns and Impairment has averaged $7.1 million across 5 years, with a median of $182000.0 in 2021.
• Biggest YoY gain for Asset Writedowns and Impairment was 47656.72% in 2021; the steepest drop was 102.16% in 2021.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $421000.0 in 2019, then plunged by 84.09% to $67000.0 in 2020, then surged by 47656.72% to $32.0 million in 2021, then sank by 96.87% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023.
• The last three Asset Writedowns and Impairment figures came in at $1.0 million (Q2 2023), -$1.0 million (Q1 2023), and $1.0 million (Q4 2022), per Business Quant data.